Large Options Trade Bets on Major Corcept Therapeutics Price Swing by 2027

A single trader has placed a large bet on significant price volatility for Corcept Therapeutics (NASDAQ: CORT), executing a classic options strategy known as a long strangle. The trade, which accounted for 97% of the session's volume at the time of the report, signals a belief that the stock will make a dramatic move in either direction by early 2027.

The Anatomy of the Trade

Options market data showed a simultaneous purchase of two large, near-identical blocks of contracts, both expiring on January 15, 2027. The structure of this long strangle is as follows:

• Bullish Leg: 4,220 out-of-the-money call options with a strike price of $140.
• Bearish Leg: 4,220 out-of-the-money put options with a strike price of $95.

This strategy is profitable only if CORT's stock price, trading around $116.56 during the session, moves substantially above the $140 call strike or below the $95 put strike by the expiration date. The negligible open interest in these contracts prior to the trade indicates this is a new position, not a hedge against an existing one.

Potential Catalysts and Market Signals

Ad

This bet on volatility aligns with several potential catalysts for Corcept. The company's outlook is heavily influenced by the sales performance of its recently launched oncology drug, LIFYORLI, and the clinical development of its drug relacorilant. Strong LIFYORLI revenue, which hit $47.6 million in its first full quarter, or positive regulatory news for relacorilant could propel the stock higher.

Conversely, potential risks include disappointing sales, the emergence of a competitor, or concerns over the stock's valuation following a 226% year-to-date surge. The source noted persistent insider selling under 10b5-1 plans in recent months. The trade is agnostic to the direction, simply betting that one of these bull or bear scenarios will cause a major price dislocation.

A Contradictory Volatility Signal

Interestingly, despite the large purchase of options—an action that typically increases their cost—the stock's 3-month implied volatility fell by 4.91 percentage points to 60.89%, according to the source. This unusual price action suggests either that the trade was part of a more complex spread or that a large institutional seller met the buyer's demand, absorbing the pressure. At the same time, a rising skew indicated that puts were becoming relatively more expensive, signaling that the market is pricing in a greater degree of downside risk.